133 related articles for article (PubMed ID: 36974795)
1. Incidence and Risk of Venous Thromboembolism in Patients With Resectable Pancreatic Cancer Receiving Neoadjuvant Chemotherapy.
Kamiya M; Kawahara S; Kamioka Y; Murakawa M; Aoyama T; Kobayashi S; Ueno M; Yamamoto N; Oshima T; Yukawa N; Rino Y; Masuda M; Morinaga S
Anticancer Res; 2023 Apr; 43(4):1741-1747. PubMed ID: 36974795
[TBL] [Abstract][Full Text] [Related]
2. Risk of Venous Thromboembolism for Patients with Pancreatic Ductal Adenocarcinoma Undergoing Preoperative Chemotherapy Followed by Surgical Resection.
Boone BA; Zenati MS; Rieser C; Hamad A; Al-Abbas A; Zureikat AH; Hogg ME; Neal MD; Zeh HJ
Ann Surg Oncol; 2019 May; 26(5):1503-1511. PubMed ID: 30652227
[TBL] [Abstract][Full Text] [Related]
3. The impact of body composition on short-term outcomes of neoadjuvant chemotherapy with gemcitabine plus S-1 in patients with resectable pancreatic cancer.
Takeda T; Sasaki T; Mie T; Furukawa T; Yamada Y; Kasuga A; Matsuyama M; Ozaka M; Sasahira N
Jpn J Clin Oncol; 2021 Apr; 51(4):604-611. PubMed ID: 33479765
[TBL] [Abstract][Full Text] [Related]
4. Venous thromboembolism prophylaxis during neoadjuvant therapy for resectable and borderline resectable pancreatic cancer-Is it indicated?
Krepline AN; Christians KK; George B; Ritch PS; Erickson BA; Tolat P; Evans DB; Tsai S
J Surg Oncol; 2016 Oct; 114(5):581-586. PubMed ID: 27760280
[TBL] [Abstract][Full Text] [Related]
5. Preoperative oncologic therapy and the prolonged risk of venous thromboembolism in resectable pancreatic cancer.
Eurola A; Mustonen H; Mattila N; Lassila R; Haglund C; Seppänen H
Cancer Med; 2022 Apr; 11(7):1605-1616. PubMed ID: 35148464
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound paclitaxel combination therapy as neoadjuvant chemotherapy for resectable/borderline resectable pancreatic ductal adenocarcinoma (PDAC-GS/GA-rP2, CSGO-HBP-015).
Yamada D; Kobayashi S; Takahashi H; Akita H; Yamada T; Asaoka T; Shimizu J; Takeda Y; Yokoyama S; Tsujie M; Tomokuni A; Tanemura M; Morimoto O; Murakami M; Kim Y; Nakahira S; Hama N; Sugimoto K; Hashimoto K; Doki Y; Eguchi H
Trials; 2021 Aug; 22(1):568. PubMed ID: 34446057
[TBL] [Abstract][Full Text] [Related]
7. A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study.
Motoi F; Satoi S; Honda G; Wada K; Shinchi H; Matsumoto I; Sho M; Tsuchida A; Unno M;
J Gastroenterol; 2019 Feb; 54(2):194-203. PubMed ID: 30182219
[TBL] [Abstract][Full Text] [Related]
8. Concurrent gemcitabine+S-1 neoadjuvant chemotherapy contributes to the improved survival of patients with small borderline-resectable pancreatic cancer tumors.
Masui T; Doi R; Kawaguchi Y; Sato A; Nakano K; Ito T; Anazawa T; Takaori K; Uemoto S
Surg Today; 2016 Nov; 46(11):1282-9. PubMed ID: 26860274
[TBL] [Abstract][Full Text] [Related]
9. A case of necrotic enteritis during neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic ductal adenocarcinoma.
Furukawa T; Sasaki T; Ono Y; Kawano F; Takamatsu M; Mori C; Mie T; Yamada Y; Okamoto T; Takeda T; Kasuga A; Matsuyama M; Ozaka M; Takahashi Y; Sasahira N
Clin J Gastroenterol; 2021 Oct; 14(5):1571-1577. PubMed ID: 34255287
[TBL] [Abstract][Full Text] [Related]
10. Comparison the efficacy and safety of different neoadjuvant regimens for resectable and borderline resectable pancreatic cancer: a systematic review and network meta-analysis.
Li X; Huang J; Jiang C; Chen P; Quan Q; Jiang Q; Li S; Guo G
Eur J Clin Pharmacol; 2023 Mar; 79(3):323-340. PubMed ID: 36576528
[TBL] [Abstract][Full Text] [Related]
11. Venous thromboembolism risk in patients receiving neoadjuvant chemotherapy for bladder cancer.
Garas SN; McAlpine K; Ross J; Carrier M; Bossé D; Yachnin D; Mallick R; Cagiannos I; Morash C; Breau RH; Lavallée LT
Urol Oncol; 2022 Aug; 40(8):381.e1-381.e7. PubMed ID: 35581123
[TBL] [Abstract][Full Text] [Related]
12. Predictors of Poor Pathological Response to Neoadjuvant Gemcitabine Plus S-1 Chemotherapy in Patients With Pancreatic Ductal Adenocarcinoma.
Mori S; Aoki T; Sakuraoka Y; Shimizu T; Yamaguchi T; Park KH; Matsumoto T; Shiraki T; Iso Y; Kubota K
Pancreas; 2021 May-Jun 01; 50(5):744-750. PubMed ID: 34016892
[TBL] [Abstract][Full Text] [Related]
13. Survival impact of neoadjuvant gemcitabine plus S-1 chemotherapy for patients with borderline resectable pancreatic carcinoma with arterial contact.
Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Nakagawa N; Takahashi S; Sueda T
Cancer Chemother Pharmacol; 2017 Jan; 79(1):37-47. PubMed ID: 27878355
[TBL] [Abstract][Full Text] [Related]
14. Venous thromboembolism during preoperative chemotherapy in the CRITICS gastric cancer trial.
Slagter AE; Sikorska K; Grootscholten C; van Laarhoven HWM; Lind P; Nordsmark M; Meershoek-Klein Kranenbarg E; van de Velde CJH; van Grieken NCT; van Sandick JW; Jansen EPM; Verheij M; Cats A
Cancer Med; 2020 Sep; 9(18):6609-6616. PubMed ID: 32735752
[TBL] [Abstract][Full Text] [Related]
15. The effect of the low stromal ratio induced by neoadjuvant chemotherapy on recurrence patterns in borderline resectable pancreatic ductal adenocarcinoma.
Kawahara K; Takano S; Furukawa K; Takayashiki T; Kuboki S; Ohtsuka M
Clin Exp Metastasis; 2022 Apr; 39(2):311-322. PubMed ID: 35000025
[TBL] [Abstract][Full Text] [Related]
16. Effect and limitation of neoadjuvant chemotherapy for pancreatic ductal adenocarcinoma: consideration from a new perspective.
Kurata Y; Shiraki T; Ichinose M; Kubota K; Imai Y
World J Surg Oncol; 2021 Mar; 19(1):85. PubMed ID: 33752677
[TBL] [Abstract][Full Text] [Related]
17. No survival benefit with suboptimal CA19-9 response: defining effective neoadjuvant chemotherapy in resectable or borderline resectable pancreatic cancer.
Liu H; D'Alesio M; AlMasri S; Hammad A; Desilva A; Lebowitz S; Rieser C; Ashwat E; Hampton E; Khachfe H; Laffey M; Singhi A; Bahary N; Lee K; Zureikat A; Paniccia A
HPB (Oxford); 2023 May; 25(5):521-532. PubMed ID: 36804826
[TBL] [Abstract][Full Text] [Related]
18. Incidence and risk of venous thromboembolism according to primary treatment in women with ovarian cancer: A retrospective cohort study.
Yuk JS; Lee B; Kim K; Kim MH; Seo YS; Hwang SO; Yoon SH; Kim YB
PLoS One; 2021; 16(4):e0250723. PubMed ID: 33909674
[TBL] [Abstract][Full Text] [Related]
19. Early detection of venous thromboembolism after the initiation of chemotherapy predicts a poor prognosis in patients with unresectable metastatic pancreatic cancer who underwent first-line chemotherapy with gemcitabine plus nab-paclitaxel.
Yamai T; Ikezawa K; Hiraga E; Kawamoto Y; Hirao T; Higashi S; Daiku K; Maeda S; Abe Y; Urabe M; Kai Y; Takada R; Nakabori T; Fukutake N; Uehara H; Fujita M; Ohkawa K
PLoS One; 2022; 17(3):e0264653. PubMed ID: 35231078
[TBL] [Abstract][Full Text] [Related]
20. Clinical Significance of Neoadjuvant Chemotherapy With Gemcitabine Plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma.
Suzuki T; Mori S; Shimizu T; Tago K; Harada N; Park KH; Sakuraoka Y; Shiraki T; Iso Y; Aoki T; Kubota K
In Vivo; 2019; 33(6):2027-2035. PubMed ID: 31662534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
